Researchers tested the performance of the whole-genome sequencing-based assay head-to-head against ctDNA and ddPCR assays.

"Dosing the first patient in the TNG456 Phase I/II trial marks a significant step for us and for patients with MTAP-deleted GBM," Adam Crystal, Tango's president of R&D, said in a statement. "People ...

NEW YORK – PeproMene Bio will expand the ongoing Phase I PMB-102 study of its BAFF-R-targeted CAR T-cell therapy PMB-CT01 after showing initial efficacy in seven lymphoma patients, the firm said ...

If regulators clear the application, the firm will begin a Phase I/II trial for RJVA-001 to assess its safety, tolerability, and initial efficacy.